Etamsylate - instructions for use, doses, side effects, contraindications

Etamsylate is a drug that prevents bleeding. Hemostatic effect is based on the enhancement of the first stage of the mechanism of hemostasis (interaction between the endothelium and platelets). The drug protects the vascular endothelium. It is proved that it increases the adhesion of platelets, stabilizes the capillary walls, thus reducing their permeability, inhibits the synthesis of those prostaglandins that cause platelet disaggregation, vasodilation and increased capillary permeability. This leads to a reduction in bleeding time and a decrease in blood loss. Ethamylate solution has no effect on the mechanism of coagulation in norm, on prothrombin time, fibrinolysis and platelet level.

Pharmacokinetics:

The drug is well absorbed after ingestion. Hemostatic effect with ingestion of etamzilate occurs in 2-4 hours. Effective concentration in the blood - 0,05-0,02 mg / ml, is evenly distributed in various organs and tissues (depends on the degree of their blood supply). Etamsylate weakly binds to plasma proteins and shaped elements of blood.

The drug is excreted from the body mainly with urine (unchanged), in an insignificant amount with bile.It is determined in significant quantities in breast milk, but there is no information on the harmful effect.

Indications:

Treatment of internal capillary bleeding of various etiologies, especially if bleeding is caused by damage to the endothelium:

- prevention and treatment of bleeding during and after surgery on well-vascularized tissues in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery;

- prevention and treatment of capillary bleeding of various etiology and localization: hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, nosebleeds, gum bleeding.

Contraindications:

Acute porphyria, hemoblastosis in children, hypersensitivity to any ingredient in the drug; thrombosis; thromboembolism.

Carefully:When bleeding against the background of an overdose of anticoagulants.

Pregnancy and lactation:

The safety of etamzilate during pregnancy is not established. Etamsylate should be used during pregnancy only if the potential benefit to the mother exceeds the possible risk to the fetus.

Breastfeeding should be stopped during treatment with a drug by the mother Etamsylate.

Dosing and Administration:

The optimal daily dose for adults is 10-20 mg / kg of body weight per day, divided into 3-4 doses. In most cases, the dose is 250-500 mg in the form of intramuscular or slow intravenous injection 3-4 times a day.

In surgery: before the operation is administered intravenously or intramuscularly 250-500 mg per hour before surgery. During the operation, 250-500 mg is intravenously administered, the administration of this dose can be repeated again. After the operation - every 6 hours for 250-500 mg until the risk of bleeding disappears.

In Pediatrics The daily dose is 10-15 mg / kg body weight, divided into 3-4 doses.

Side effects:

Headache, dizziness, redness of the face, an allergic rash, paresthesia of the lower extremities, lowering of arterial pressure, heartburn, heaviness in the epigastric region. These effects are transient.

Interaction:

Interaction with other drugs has not been observed.

Possible combination with aminocaproic acid and menadione sodium bisulfite.

Special instructions:

Care must be taken in patients who have ever had thrombosis or thromboembolism.

The drug is ineffective in patients with a reduced number of platelets.

Before starting treatment, other causes of bleeding should be ruled out.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive a car or machinery.

Form release / dosage:Tablets, 250 mg.

Packaging:

In banks of dark glass, polyethylene containers or in contour squares.

Storage conditions:In a dry place, protected from light and inaccessible to children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:N014652 / 01-2003

Date of registration:04.12.2008

The owner of the registration certificate:LUHANSKY HFZ, OJSC LUHANSKY HFZ, OJSC Ukraine

Manufacturer: & nbsp

LUHANSKY HFZ, OJSC Ukraine

Information update date: & nbsp05.10.2015

Illustrated instructions

Instructions

Etamsylate (Etamsylate)